Cepheid 2013 sales of CT/NG estimated $15M-$20M at William Blair William Blair expects solid initial demand for Cepheid's just approved Xpert CT/NG from existing Xpert customers and projects 2013 sales between $15M-$20M on a worldwide basis. However, William Blair says it is not sure if Cepheid will be able to ship enough product to meet initial demand as it provided no update on the recent manufacturing issues. The firm keeps an Outperform rating on the stock.
On The Fly: Analyst Upgrade Summary Today's noteworthy upgrades include: AB InBev (BUD) upgraded to Hold from Sell at Societe Generale... Baker Hughes (BHI) upgraded to Outperform from Sector Perform at Howard Weil... Bank of the Ozarks (OZRK) upgraded to Buy from Hold at BB&T... Bill Barrett (BBG) upgraded to Buy from Neutral at Mizuho... Cepheid (CPHD) upgraded to Buy from Hold at Cantor... Cigna (CI) upgraded to Positive from Neutral at Susquehanna... Extra Space Storage (EXR) upgraded to Buy from Hold at Jefferies... GNC Holdings (GNC) upgraded to Outperform from Neutral at Wedbush... MB Financial (MBFI) upgraded at DA Davidson... Mondelez (MDLZ) upgraded to Buy from Hold at Societe Generale... Radian Group (RDN) upgraded to Buy from Neutral at Compass Point... Skullcandy (SKUL) assumed with a Overweight from Neutral at Piper Jaffray... Under Armour (UA) upgraded to Overweight from Neutral at Piper Jaffray.